Bio Screening Industry News

MILFORD, Mass. (Oct. 24, 2008) - Thermo Fisher Scientific Inc., the
world leader in serving science, has introduced new Thermo Scientific
PocketTip(r) D.A.R.T.s(r) tips, enabling nanoliter volume dispensing on
Thermo Scientific Matrix automated systems. An internally molded
capillary pocket allows the transfer of 50-500 nL of concentrated sample
compounds suspended in Dimethyl Sulphoxide (DMSO) directly to assay
plates, saving time, reagents and labware, as well as improving data
quality with in-tip mixing.

PocketTip D.A.R.T.s tips introduce an easy, low risk and reliable method
to change the way in which current instrumentation performs critical
liquid handling tasks. Through aspiration, the capillary pocket fills
with the specified amount of compound solution and facilitates soft
in-tip mixing of sample and assay material, removing time consuming
intermediate dilution steps and adding further function to the existing
instruments. Furthermore, the unique face seal of the D.A.R.T.s tip
minimizes tip-to-tip height variations for consistent dispensing. This
innovative pipetting method makes it possible to perform assays quicker,
reduce reagent costs and prevent compound precipitation for more
accurate and precise results.

The new PocketTip D.A.R.T.s tips are ideal for all secondary compound
screening applications, such as selectivity assays, potency
determinations, cell- and enzyme-based assays and PCR primer dilutions.
For further information, please see www.thermo.com/matrix.

Thermo Scientific is part of Thermo Fisher Scientific, the world leader
in serving science.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving
science, enabling our customers to make the world healthier, cleaner and
safer. With annual revenues of $10 billion, we have more than 30,000
employees and serve over 350,000 customers within pharmaceutical and
biotech companies, hospitals and clinical diagnostic labs, universities,
research institutions and government agencies, as well as environmental
and industrial process control settings. Serving customers through two
premier brands, Thermo Scientific and Fisher Scientific, we help solve
analytical challenges from routine testing to complex research and
discovery. Thermo Scientific offers customers a complete range of
high-end analytical instruments as well as laboratory equipment,
software, services, consumables and reagents to enable integrated
laboratory workflow solutions. Fisher Scientific provides a complete
portfolio of laboratory equipment, chemicals, supplies and services used
in healthcare, scientific research, safety and education. Together, we
offer the most convenient purchasing options to customers and
continuously advance our technologies to accelerate the pace of
scientific discovery, enhance value for customers and fuel growth for
shareholders and employees alike. Visit www.thermofisher.com.

LEXINGTON, Mass. (USA), and HEIDELBERG, Germany, Oct. 20, 2008 - The German Cancer
Research Center, also known as DKFZ, in Heidelberg (Germany) chose febit´s newly
introduced Geniom® RT Analyzer to investigate the association of microRNAs (miRNAs)
and cancer.

miRNAs are small pieces of RNA with a maximum length of 23 nucleotides, which have
become an important focus of life-science research in the past couple of years.
Since they do not encode any proteins, they remained largely unappreciated for many
decades. Recently, however, scientists began to realize their crucial role in the
regulation of intracellular events such as differentiation or apoptosis of cells.
The number of miRNA being discovered is growing by the day.

DKFZ scientists therefore searched for a technology that would allow them to keep
pace with the rapidly evolving miRNA databases, continually incorporating the latest
information into their research on the role of miRNAs in carcinogenesis. The newly
developed Geniom RT Analyzer ideally meets this requirement: it exploits freely
configurable biochips produced on demand at febit for microarray analysis of miRNA
profiles in biological samples.

“Our positive experience with the flexibility of febit´s Geniom contributed to our
decision to use the new Geniom RT Analyzer,” said Joerg Hoheisel, director of the
DKFZ Functional Genome Analysis Division. “Preliminary tests indicate an excellent
quality of microarray analysis. In addition, my team is enthusiastic about the
straight-forward operation and outstanding efficiency of the instrument.”

In addition to flexibility, the Geniom RT Analyzer offers a high degree of
automation and nume­rous user-friendly features: all steps in the workflow,
including sample addition, hybridization, staining, washing, shaking and detection,
are performed in one single instrument requiring a minimum of operator time. The
efficient operation results with minimal error rates and offer consistent
experimental parameters providing highly reproducible results. Data read out by the
Geniom Wizard software may then be analyzed with standard software solutions.

In addition to miRNA analysis, the Geniom RT Analyzer offers a variety of other
high-performance applications. For example, a patented biochip protocol enables the
fragmen­tation and sorting of large genomes in smaller well-defined fractions.
Without this essential fractionation step, the complexity of the genomic DNA would
preclude any effective analysis. These may then serve as samples in mutation
analysis and high-throughput sequencing with next-generation sequencers.

febit’s new Geniom RT Analyzer combines extraordinary flexibility with a high degree
of automation for microarray analysis. (Photo: febit)

About febit

febit enables scientists to read, write and understand the code of life: DNA. With
its unique Geniom technology and services, febit is the only company that puts the
control of simplified genomic research in the hand of the user. The seamless
integration of DNA synthesis and analysis and the superior support in experiment
design and bioinformatics helps to understand data and turn it into results. febit’s
team of experienced scientists is dedicated to support customers to solve the
challenge of understanding biological processes. Geniom is a technological and
service platform successfully implemented in basic and applied research by renowned
institutions and companies. Geniom exploits cutting-edge microarray technology for
analysis and synthesis of genes and genomes, providing superior time- and
cost-efficiency combined with an unsurpassed spectrum of applications.

For more information about febit and its products please visit

www.febit.com

About the DKFZ, Division of Functional Genome Analysis

Research at the division of Functional Genome Analysis at the DKFZ (German Cancer
Research Center) aims at the development and immediate application of new
technologies for the production and processing of molecular information at a global
cellular level. The overall objectives are an analysis, assessment and description
of the realisation of cellular function from genetic information as well as the
understanding of the regulation of the relevant processes. Many projects are pursued
in national and international collaborations and programmes.

For more information on Functional Genome Analysis at the DKFZ, please visit
www.dkfz.de/funct_genome/

CAMBRIDGE, Mass., Oct 24, 2008 (BUSINESS WIRE) — Hydra Biosciences, a privately held biopharmaceutical company focused on developing novel drugs using its expertise in Transient Receptor Potential (TRP) ion channels, announced today the expansion of its executive management team with the appointments of David Kimball, Ph.D. as Chief Scientific Officer and Christine Bellon, Ph.D. as Vice President of IP and Legal Affairs. Dr. Kimball most recently served as Senior Vice President, Discovery, at Pharmacopeia. Dr. Bellon joins Hydra from Infinity Pharmaceuticals, where she served as Assistant General Counsel, Intellectual Property.
“We are excited to add the demonstrated scientific, business and legal acumen of Christine and David to an already talented management team, and believe their appointments are indicative of the broader near-term growth potential for our organization,” said Russell Herndon, President and Chief Executive Officer of Hydra. “David and Christine will each play a key role in advancing and building upon the strong IP position of our deep and competitively differentiated pipeline of TRP ion channel antagonists and agonists in development for the treatment of pain, inflammatory disease, pulmonary dysfunction, and other indications.”
Dr. Kimball joins Hydra with 25 years of experience in the discovery and development of small molecule drug candidates. At Pharmacopeia Dr. Kimball was responsible for research alliances as well as drug discovery research from target identification through preclinical development. During his six years at Lexicon, Dr. Kimball built the company’s discovery capability with direct responsibility for Lexicon’s small molecule pipeline. Dr. Kimball grew and managed an organization of over 75 chemists, including medicinal, analytical, computational, process research and development, library synthesis and outsourcing chemistry. Prior to joining Lexicon, Dr. Kimball spent nearly 20 years at Bristol-Myers Squibb Pharmaceutical Research Institute, most recently as Research Fellow in the Division of Medicinal Chemistry. During his tenure at BMS, Dr. Kimball led several significant drug discovery and development research efforts that culminated in clinical compounds. An Associate Member of the graduate faculty at Rutgers University School of Pharmacy since 1989, Dr. Kimball received his Ph.D. in Organic Chemistry/Chemical Biology from the State University of New York at Stony Brook.
Dr. Bellon brings more than 15 years of experience in intellectual property law to Hydra. Dr. Bellon came to Hydra from Infinity Pharmaceuticals, where she held the position of Assistant General Counsel, Intellectual Property. Prior to her position at Infinity Pharmaceuticals, Dr. Bellon served as patent counsel at Wyeth Pharmaceuticals, where she was responsible for the company’s small molecule cardiovascular and metabolic disease patent portfolio and structural biology patent portfolio. Earlier in her career, Dr. Bellon was an attorney in the Boston office of Fish & Richardson P.C., where her practice focused on patent prosecution and client counseling in the areas of pharmaceuticals, chemicals, polymers, and biotechnology. Dr. Bellon received a B.S. in Chemistry from Yale University, and holds a Ph.D. in Organic Chemistry from the Massachusetts Institute of Technology and a J.D. degree from Columbia Law School.
About TRP Ion Channels
Ion channels have been implicated in many diseases, including hypertension, cardiac arrhythmias, gastrointestinal disorders, cystic fibrosis and pathological pain. Many drugs on the market today act on ion channels, either directly or indirectly, including calcium channel blockers for hypertension and angina, and sodium channel blockers for pain. Hydra’s TRP channel discovery program has identified numerous modulators predicted to impact diseases such as pain and inflammation, hypertension, and pulmonary diseases. Many of these modulators have been shown to be efficacious in animal models of disease. In addition, ion channels have been successful drug targets, with modulators of ion flux representing up to 17% of world pharmaceutical sales.
About Hydra Biosciences
Hydra Biosciences, a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra’s proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. More information about Hydra Biosciences is available at: www.hydrabiosciences.com.

The inaugural Drug Discovery Latin America conference and exhibition will be held in the colourful city of Rio de Janeiro in the days immediately following the world famous carnival.

The purpose of this meeting is to review the status of drug discovery activities in Latin America and to assist its future development. Business and research leaders from both developed markets and BRIC countries will bring their knowledge and experience to share. Participants will be encouraged to network and explore partnering opportunities.

Full conference passes include admission to all sessions and the exhibition as well as conference documentation.
Lunch, coffee breaks and the drinks reception provide ample time for networking and to continue discussions from the question and answer sessions.

http://www.selectbiosciences.com/conferences/DDLA2009

Agenda

Day One - 26 February 2009

Screening

09:00

Using Drug Molecules as Probes and Probe Molecules as Drug Precursors
Ralph Garippa, Research Leader, Roche Discovery Technologies
This talk will highlight some examples of Pharma’s HT screened molecules which became popular commercialized reagents, and some promising molecules which have been published in the public domain (PubMed) as a result of academic screening.

09:30

Title to be Confirmed
Jeremy Caldwell, Director of Cell Based Screening, GNF

10:00

Using in vitro Screening Assays to Profile the Biology of Chemical Entities
John Watson, Director, Pharmacology and Biotechnology, Promega
Profiling of a compound’s impact on cell signaling pathways, ADME properties and cellular toxicity early in the discovery process can help prioritize compounds to help assure the final drug has maximal target activity and minimal off target effects.

10:30

Coffee and Networking in the Exhibition Hall

11:15

Nuclear Receptor Activation Assessment: Improving Safety and Directing Chemistry
Kyle Kramer, Vice President, Business Development, Puracyp
The presentation includes introduction to key nuclear receptors (NR) involved in drug metabolism. The construction and use of stable cell lines with reporter genes is explained. Finally, the utility of these systems in drug safety screening is presented.

11:45

Functional Genome-Wide Screening for Genes that Regulate p53 in Endothelial Cells
Michael Edel, Principle Investigator, Centre of Regenerative Medicine in Barcelona
Angiogenesis requires an increase in endothelial cell proliferation to support an increase in mass of blood vessels. An in vitro cell model has been designed that can be used for screening gene or chemical libraries that regulate endothelial cell proliferation.

12:15

Presentation to be Announced

12:45

Lunch and Networking in the Exhibition Hall

Tropical Disease Drug Development

14:00

Prolyl Oligopeptidase of Trypanosoma cruzi (POP Tc80) : A Target for the Design of New Weapons Against Chagas Desease
Bernard Maigret, CNRS Research Director, LORIA - Nancy University
The group has recently demonstrated that the activity of POPTc80, a prolyl endopeptidase that mediates native collagen and fibronectin hydrolysis, is required for trypomastigotes entry into host cells. Using a tridimentionnel model of this target built from homology modelling, molecular docking and screening assays they were able to identify possible new compounds active against Chagas desease.

14:30

Novel Drug Targets for the Malaria Parasite
Asif Mohmmed, Staff Research Scientist, International Centre for Genetic Engineering and Biotechnology

15:00

Title to be Confirmed
Leila de Mendonça Lima, Senior Researcher and Head of Lab. for Functional Genomics and Bioinformatics, Oswaldo Cruz Foundation, FIOCRUZ

15:30

Coffee and Networking in the Exhibition Hall

16:15

Drug Discovery of Fluorinated Drugs Against Neglected Diseases and HIV/AIDS
Núbia Boechat, Head of R&D Group in Medicinal Chemistry, Oswaldo Cruz Foundation, FIOCRUZ
Organic synthesis of fluorinated compounds in medicinal chemistry against AIDS and neglected diseases; innovation and technological management in public health.

Drug Discovery in Emerging Markets

16:45

Drug Development and Discovery
Christopher Bianca, Professor of Chemistry, Clinical Consultant, Keystone College Academia
This presentation discusses all the relevant information required to develop a new drug or a lead compound drug, from toxicology, to pharmacodynamics, to pharmacokinetics, and all the way to clinical trials including FDA approval.

17:15

Stem Cells in Drug Discovery
Chris Kendrick-Parker, Chief Commercial Officer, Cellular-Dynamics International

17:45

Drinks Reception

Day Two - 27 February 2009

Drug Discovery in Emerging Markets (continued)

09:00

Title to be Confirmed
Marcelo Criscuolo, Executive Director, Bio Sidus

09:30

Ranbaxy’s Quest to Become a Research Based International Pharmaceutical Company
Abhijit Ray, Director, New Drug Discovery Research, Ranbaxy Laboratories
Ranbaxy has worked hard to create physical infrastructure, science base and a sustainable strategy for drug discovery research. How this effort has borne fruit will be discussed.

10:00

Taking Companies from Concept to Market
Paul Morril, Co-Founder, Execute Technologies

10:30

Coffee and Networking in the Exhibition Hall

11:15

Title to be Confirmed
Jose Krieger, Heart Institute (InCor), University of Sao Paulo

11:45

Comparative Proteomics Identification of Diagnostic and Prognostic Biomarkers in Leukemias
Eliana Abdelhay, Head of the Bone Marrow Transplantation Laboratory, National Cancer Institute (INCA)
Through proteomics the group analyzed the modifications in the protein profile of bone marrow MNCs from patients in CML phases and in Imatinib Mesylate treatment. They could identify several putative biomarkers of diagnostic, evolution and treatment response that can be use in drug design.

12:15

NFAT Transcription Factors: A Putative New Target in Cancer
João Viola, Head, Division of Cell Biology, National Cancer Institute (INCA)
The Nuclear Factor of Activated T Cells (NFAT) family of transcription factors is activated upon different stimuli that lead to increased intracellular calcium levels. NFAT proteins regulate genes that control many aspects of malignant cell transformation and tumour development. The group investigates the molecular mechanisms by which NFAT regulate tumour-related events and its involvement in oncogenesis.

12:45

Lunch and Networking in the Exhibition Hall

Natural Products

14:00

ChemBioBank, an Academic Project for Drug Discovery in Latin America
Fernando Albericio, Executive Director, Barcelona Science Park, University of Barcelona
The goal of the Latin American ChemBioBank project (LA-CBB) is to build a chemico-biological database, annotated with both biological and bioinformatic data, addressed to the scientific community and to the pharmaceutical and biotech industries.

14:30

High Content Screens for Novel Antipoxviral Agents: Natural Products to the Rescue
Hakim Djaballah, Director, Memorial Sloan Kettering Cancer Centre
The group have developed and validated a high content assay to screen for compounds that would preferentially block viral entry, viral replication, or viral spread upon infecting cell monolayer seeded in 384-well plates with a recombinant vaccinia virus which expresses karyophilic GFP under the control of a viral early/late promoter.

15:00

Using a Luciferase Based Screening Assay to Identify Traditional Chinese Medicine Targeting Nuclear Hormone Receptors
Chiwai Wong, Principal Investigator, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences
Since the activities of nuclear hormone receptors (NHRs) are regulated by small molecule compounds and that Traditional Chinese Medicine (TCM) extracts contain a diverse array of naturally derived chemicals, the group investigated if selective TCM extracts modulate the activities of NHRs.

15:30

Coffee and Networking in the Exhibition Hall

16:15

Bourreria huanita Flowers, a New Antidepressant?
Miguel Torres, Biological Chemist, University of San Carlos
Ethnobotanical and pharmacological studies have preliminarily demonstrated an antidepressant effect in ethanolic extract of dried Bourreria huanita (Boraginaceae) flowers from Guatemala. It’s possible this natural product contains a medically useful molecule and funding is required to continue the chemical analysis and elucidation.

16:45

Post Absorption and Metabolism Compounds: A New Approach to Discover Drug Candidates from Chinese Herbal Medicine
William Jia, VP Research and Associate Professor, Shanghai Innovative Research Centre/University of British Columbia
In a recent study the group has isolated compounds post absorption/metabolism (PAM) of orally taken ginseng. The study showed that those compounds are highly active for neuroprotection and anti-depression.

MANCHESTER, United Kingdom & STAMFORD, Conn.–Tepnel Life Sciences PLC (AIM:
TED) today announced that it has expanded its molecular genetic services
offering through the addition of Illumina’s iScan System, a next-generation
scanner that provides researchers conducting genetic variation studies with
significantly greater throughput and application diversity. This
announcement marks the first anniversary of Tepnel’s new pharmaceutical
services facility and makes Tepnel the first commercial provider of iScan
services within the UK.

Combined with Tepnel’s established range of upstream and downstream genetic
capabilities, the Company now offers a full suite of complementary services
from DNA extraction through to Bioinformatics. Illumina’s iScan platform
supports both human and non-human applications and is capable of generating
up to 225 million genotypes per day.

Tepnel also has a variety of other platforms and techniques for SNP-based
investigations for both human and non-human research and clinical
applications. This breadth of service enables Tepnel to provide a complete
solution from DNA extraction through to SNP genotyping and DNA sequencing,
all undertaken in accordance with Good Laboratory Practice (GLP).

“Tepnel can offer customers a broad portfolio of innovative genetic analysis
assays some of which are supported on our new high-throughput iScan reader,”
said David Scott, General Manager of Tepnel’s Livingston facility. “This new
addition to our service opens up the possibility to our customers of whole
genome association, focused content analysis, copy number variation analysis
and, epigenetics on both human and non-human samples, all within a
regulatory compliant environment.”

“Accelerating and expanding our molecular genetic services at this rapid
pace reflects our commitment to the long-term strategy of building Tepnel’s
market presence in the fast-growing sectors of
pharmacogenomics/pharmacogenetics and genetic disease disposition testing,”
said Allan Brown, Managing Director, Tepnel Research Products & Services.

About Tepnel Life Sciences plc

Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences
products and services Group with two divisions, Molecular Diagnostics and
Research Products & Services. The Company has laboratories, manufacturing
and operations in the USA, UK and France with over 200 employees. Tepnel
provides test kits, reagents and services to two highly synergistic markets,
these being Molecular Diagnostics and Biomedical Research. The Company’s
strategy has been to identify high growth niche opportunities within these
multi-billion pound markets. Tepnel focuses on these niche operations with
internally developed products, patents, expertise and know-how as well as
strategic acquisitions, to develop a leadership position within these
defined market segments. For more information please visit www.tepnel.com.

San Jose, CA October 16, 2008

Matrix metalloproteinases (MMPs) belong to a family of secreted or membrane-associated zinc endopeptidases involved in both normal and diseased tissue remodeling. They are capable of degrading all kinds of extracellular matrix (ECM) proteins, but also can process a number of bioactive molecules. MMPs are key players in normal and pathological processes, including embryogenesis, wound healing, inflammation, arthritis, and cancer.

MMPs share common structural and functional elements and are products of different genes. The three common domains include the pro-peptide, the catalytic domain and the haemopexin-like C-terminal domain linked to the catalytic domain by a flexible hinge region. MMPs are initially synthesized as inactive (latent) zymogens with a pro-peptide domain that must be removed before the enzyme is active.

AnaSpec is pleased to complement its MMP product line with a suite of SensoLyteTM MMP ELISA Kits. These kits are ideal for quantitative detection of MMP proteins (latent and active forms) in serum, plasma, cell culture supernates and urine. The SensoLyteTM ELISA Kits use a convenient, 96-well plate based format with colorimetric read-out.

AnaSpec?s widely used fluorescent SensoLyteTM MMP Activity Assays measure active MMPs in a convenient, 96-well plate-based method with highly sensitive fluorimetric read-out. A colorimetric read-out MMP Activity Assay kit is also available.

About AnaSpec

AnaSpec is a leading provider of integrated proteomics solutions to the world?s largest biotech, pharmaceutical, and academic research institutions.  With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and combinatorial chemistry.

For more information visit www.anaspec.com

London, UK – 17 October 2008: Research by scientists collaborating with specialist product development consultancy, Bio Nano Consulting (BNC), into the workings of vancomycin - one of the few antibiotics that can be used to combat increasingly resistant infections such as MRSA - has been published in Nature Nanotechnology (October 2008). The researchers, led by Dr Rachel McKendry and Professor Gabriel Aeppli at the London Centre for Nanotechnology, developed novel, ultra-sensitive nanomechanical probes capable of providing new insight into how antibiotics work, paving the way for the development of more effective new drugs.

Commenting on the new research, Bio Nano Consulting CEO, Dr David Sarphie said “BNC was set up specifically to help companies apply nanotechnology tools to address real-world biomedical problems such as antimicrobial resistance. Working with the BNC allows companies access scientists who have expertise in numerous ground-breaking nanotech-related research areas, and this paper in Nature Nanotechnology is a great example of the highest quality research that they are undertaking.”

During the study Dr McKendry, Joseph Ndieyira, Moyu Watari and coworkers used cantilever arrays – tiny levers no wider than a human hair – to examine the process which ordinarily takes place in the body when vancomycin binds itself to the surface of the bacteria. They coated the cantilever array with mucopeptides from bacterial cell walls and found that as the antibiotic attaches itself, it generates a surface stress on the bacteria which can be detected by a tiny bending of the levers. The team suggests that this stress contributes to the disruption of the cell walls and the breakdown of the bacteria.

The interdisciplinary team went on to compare how vancomycin interacts with both non-resistant and resistant strains of bacteria. The ‘superbugs’ are resistant to antibiotics because of a simple mutation which deletes a single hydrogen bond from the structure of their cell walls. This small change makes it approximately 1,000 times harder for the antibiotic to attach itself to the bug, leaving it much less able to disrupt the cells’ structure, and therefore therapeutically ineffective.

“There has been an alarming growth in antibiotic-resistant hospital ‘superbugs’ such as MRSA and vancomycin-resistant Enterococci (VRE),” said Dr McKendry. “This is a major global health problem and is driving the development of new technologies to investigate antibiotics and how they work.

“The cell wall of these bugs is weakened by the antibiotic, ultimately killing the bacteria,” she continued. “Our research on cantilever sensors suggests that the cell wall is disrupted by a combination of local antibiotic-mucopeptide binding and the spatial mechanical connectivity of these events. Investigating both these binding and mechanical influences on the cells’ structure could lead to the development of more powerful and effective antibiotics in future.”

Established in late 2007, BNC provides a seamless concept-to-market route for the bio-nanotechnology sector.

Image caption:
A schematic representation to show the nanomechanical detection of antibiotic-peptide interactions on multiple cantilever arrays. The blue and white structures show chemical binding interaction between vancomycin and the bacterial mucopeptide analogue, DAla. The red line represents the mechanical connectivity of the chemically reacted regions on the cantilever.

For more information please visit www.bio-nano-consulting.com

Editors’ notes

About the paper and authors:
The article ‘Nanomechanical Detection of Antibiotic Mucopeptide Binding in a Model for Superbug Drug Resistance’ by J. W. Ndieyira et al., was published in Nature Nanotechnology, October 12 2008.

About Bio Nano Consulting
The BNC is a specialist research and development consultancy operating in the convergent field of bionanotechnology. A joint venture of Imperial College London and University College London, the BNC is funded through the Technology Strategy Board (TSB) with additional support from the London Development Agency (LDA).

Along with its partner organisation, the National Physical Laboratory, the BNC offers a service to the biomedical and healthcare industries in microsystems and nanotechnology. This encompasses design, 3-D modelling and visualisation, rapid prototyping, and characterisation.

Brady Freezerbondz labels overcome the virtually impossible task of labelling already frozen samples. Gone are the days where a sample needs to be thawed before a tracking and identification label can be applied. Now with Freezerbondz labels, you can quickly and easily identify samples in their frozen state.

www.bradylab.com

Bibby Scientific announces an addition to the Techne range of personal thermal cyclers – the expanded capacity TC-3000X. With a highly successful half-century track record in the design and manufacture of temperature control equipment, Bibby Scientific’s world-leading Techne brand is synonymous with robust, reliable, reproducible DNA amplification.

www.bibby-scientific.com